Cipla Gets Nod for Insulin Inhalation Powder: Afrezza

By By Rediff Money Desk, New Delhi
Dec 11, 2024 17:34
Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only non-injectable insulin for both type 1 and type 2 diabetes.
New Delhi, Dec 11 (PTI) Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.

Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus.

By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement.

Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections.

Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream.

Afrezza starts working as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals.

The effect of the drug lasts for about 2-3 hours and it closely resembles the body's response to insulin.

This is the first and only non-injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus, the drug firm said.

"By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively," Cipla MD and Global CEO Umang Vohra said.
Source: PTI
Read More On:
ciplaafrezzainsulindiabetesinhalationdiabetes managementcdscomannkindnon-injectable insulintype 1 diabetestype 2 diabetes
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Akasa Air Pilot Concerns: Safety Issues Alleged

Akasa Air faces allegations of training and safety issues from a section of its pilots...

Pune Property Registrations Down 11% in...

Pune property registrations fell 11% year-on-year in November, despite strong demand,...

Maxivision Eye Hospitals Expands in Gujarat,...

Maxivision Super Specialty Eye Hospitals is expanding its presence in Gujarat with a Rs...

Senco Gold Raises Rs 459 Crore via QIP

Senco Gold Limited raised Rs 459 crore through a Qualified Institutions Placement (QIP)...

Eleganz Interiors Files IPO on NSE Emerge

Eleganz Interiors, a leading interior fit-out solutions provider, has filed IPO papers...

China to Invest USD 1 Billion in Pakistan...

China pledges USD 1 billion to establish a medical city in Pakistan, further...

Worldwide Realty Invests Rs 320 Cr in Haryana...

Worldwide Realty is investing Rs 320 crore to develop a 22-acre housing project in...

Dak Sewa is Jan Sewa: India Post to Go Digital,...

India Post is undergoing a digital transformation to become a leading logistics...

E-commerce Safety Pledge: Protecting Online...

Major e-commerce platforms in India commit to a Safety Pledge on Dec 24, aiming to...

Ira Bindra Named Group President of Reliance...

Mukesh Ambani appoints Ira Bindra as Group President for human resources at Reliance...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2024 Rediff.com